Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease.

Trial Profile

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Expanded access
  • Most Recent Events

    • 14 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jan 2012 Additional lead trial investigator (Seema Singhal) identified as reported by Robert H. Lurie Comprehensive Cancer Center, Northwestern University.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top